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 1 
Interpretive summary. Use of on-farm data to guide treatment and control of mastitis caused by 2 
Streptococcus uberis, by Samson et al. To reduce the risk of antimicrobial resistance, judicious use of 3 
antimicrobials is advocated. We show that routinely available DHI and treatment data can be used in 4 
veterinary practice to predict cure of S. uberis mastitis. Probability of apparent cure is higher among 5 
1st and 2nd parity animals compared to older cows, and in animals with short-duration elevated SCC 6 
compared to those with repeated SCC elevation before occurrence of mastitis. This knowledge 7 
enables farmers and veterinarians to tailor antimicrobial use for treatment of mastitis, and to put 8 
increased emphasis on prevention of cases with poor prognosis.  9 
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ABSTRACT 33 
 34 
Treatment of mastitis is the most common reason for use of antimicrobials in dairy cattle. The 35 
responsible use of antimicrobials could be strengthened by knowledge of predictors for cure, which 36 
would help to tailor treatment decisions. Ideally, to allow for widespread uptake, this would be 37 
achieved using data that are routinely available. To assess whether this is feasible in practice, 38 
farmers were invited to submit milk samples from mastitis cases to their veterinary practice for 39 
bacteriological culture. Among 624 culture-positive samples, 251 were positive for Streptococcus 40 
uberis. Using cow-level data, cases were classified as severe clinical mastitis (CM; “severe”), 1st non-41 
severe CM (“first”), repeated non-severe CM (“repeat”), or subclinical mastitis (“subclinical”). 42 
Additional data were collected at cow-level (somatic cell count (SCC), parity, lactation stage, milk 43 
yield, fat and protein content, treatment) and at herd-level (housing, bedding, pre-milking teat 44 
disinfection, post-milking teat disinfection). Severe cases were overrepresented among heifers and 45 
animals in early lactation whereas repeat cases were overrepresented in cows with 3 or more 46 
lactations. The probability of cure was higher among 1st and 2nd parity animals than among older 47 
cows, and higher in animals with a single elevated cow-level SCC than in animals with multiple high 48 
SCC records. Results obtained in the current study are similar to those previously described for 49 
Staphylococcus aureus mastitis. Thus, routinely available cow-level information can help to predict 50 
the outcome of antimicrobial treatment of the most common causes of Gram-positive mastitis.  51 
 52 
Key words: mastitis, Streptococcus uberis, prognosis, antimicrobial treatment, clinical manifestation  53 
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INTRODUCTION 54 
 55 
Antimicrobial resistance is increasingly perceived as a threat to human and animal health and the 56 
need for responsible use of antimicrobials is emphasized by a range of national and international 57 
bodies (UK Department of Health 2013; World Health Organisation 2015). Key elements of the 58 
approach proposed by the World Health Organisation (WHO) include reduction of the incidence of 59 
infection and optimized use of antimicrobial medicines (WHO, 2015). Farmers are increasingly aware 60 
of the need to use antimicrobials responsibly. In a recent survey in the UK over 70% of dairy farmers 61 
said that reducing antibiotic usage would be “a good thing to do” (Jones et al., 2015). Veterinarians 62 
can play an important role in this process by providing information on ways to achieve reductions in 63 
antibiotic usage, e.g. by minimizing the risk of disease or through development of treatment 64 
protocols (Raymond et al., 2006; Jones et al., 2015). 65 
On dairy farms, treatment of mastitis is a major reason for use of antimicrobials. For 66 
example, Pol and Ruegg (2007) calculated the estimated overall exposure to antimicrobial drugs of 67 
cattle on conventional dairy farms as 5.43 defined daily doses (DDD) per cow per year. This included 68 
3.58 DDD of intramammary applications (2.02 DDD during lactation and 1. 56 DDD at dry off) and 69 
1.85 DDD of parenteral use. Clinical mastitis (CM) was the most common reason for intramammary 70 
or parenteral antimicrobial usage. To reduce the use of antimicrobials protocols for selective 71 
treatment of dry cows and cattle with CM have been developed, including protocols based on 72 
culture and on cow-factors such as SCC (Lago et al., 2011; Cameron et al., 2014; Scherpenzeel et al., 73 
2014). In culture-based protocols, treatment decisions are largely based on the distinction between 74 
gram-positive growth, gram-negative growth and no growth (Lago et al., 2011; Cameron et al., 75 
2014). Further refinement of treatment decisions may be possible when pathogen factors, such as 76 
antimicrobial resistance, and host characteristics, including duration of infection and parity, are 77 
taken into account, but this has only been described in detail for Staphylococcus aureus (Barkema et 78 
al., 2006). 79 
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 In many countries on different continents Streptococcus uberis is among the most common 80 
gram-positive causes of CM (Olde Riekerink et al., 2008; Petrovski et al., 2011; Verbeke et al., 2014). 81 
The organism is also responsible for a considerable proportion of subclinical mastitis cases (Bradley 82 
et al., 2007; Sampimon et al., 2009). Intramammary infections and CM caused by S. uberis can be 83 
transient, recurrent or chronic and a wide range of cure rates has been reported in response to 84 
treatment (Zadoks et al., 2003; Zadoks 2007). Despite its importance as a mastitis pathogen little is 85 
known about risk factors for the clinical manifestation or treatment outcome of S. uberis IMI. 86 
Therefore, the aim of this study was to generate data that could inform guidelines for improved 87 
management of S. uberis mastitis under field conditions. To that end, we conducted a farm-based 88 
study of herd- and cow-level risk factors that are associated with the clinical manifestation and 89 
likelihood of apparent cure of S. uberis IMI as based on SCC. In doing so, we only used tools and data 90 
that are routinely available to farmers and veterinary practices, including treatment and DHI records, 91 
because our aim was to generate low-cost guidelines for improved management of S. uberis mastitis 92 
under field conditions.   93 
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MATERIALS AND METHODS 94 
 95 
Milk sampling and Bacteriological culture 96 
From August 2012 until January 2014, quarter milk samples (n=624) were collected from French 97 
dairy cows with clinical or subclinical mastitis using standard aseptic sample collection methods 98 
(National Mastitis Council, 1999). Detection and sampling of mastitis cases was driven by 99 
participating farmers. To motivate farmers to participate in the study, all clients of our veterinary 100 
practice (Vetformance, Villaines la Juhel, France) with more than 50 lactating cows (approximately 101 
500 farms), received an invitation to sample clinical and subclinical mastitis cases at their farms. The 102 
bacteriological analysis of the samples was free of charge for the farmers. In addition, upon return of 103 
completed data information sheets, a head collar for a cow was offered to the farmers. One hundred 104 
and forty two farmers submitted at least one milk sample, indicating an uptake of approximately 105 
28%.  106 
Milk samples were subjected to bacteriological culture in the laboratory of Vetformance. 107 
Aliquots of milk (10 µl) were plated onto three media, i.e. (1) Colombia blood agar containing 5% 108 
sheep blood (bioMérieux, Craponne, France; Ref. 43041); (2) Colistin Nalidixic Acid (CNA) agar (blood 109 
agar plate containing 5% sheep blood, Colistin (10 mg/L) and Nalidixic Acid (15 mg/L) (bioMérieux; 110 
Ref. 43071) and (3) Bromo Cresol Purple (BCP) agar (bioMérieux;  Ref. 43021). Plates were incubated 111 
at 37°C for 18 to 24 h. Cultures were considered pure if only one morphotype was present on the 112 
blood agar plate. For pure cultures, growth on both the CNA and BCP plates was considered as 113 
evidence of the bacteria being gram-positive; growth on only the BCP plate as evidence of the 114 
bacteria being gram-negative. Among gram-negative bacteria, E.coli was characterized by a positive 115 
lactose reaction (colour change of the BCP plate from purple to yellow) and a negative urea reaction 116 
(bioMérieux; Ref. 55752), whereas Klebsiella was identified by both positive lactose and positive 117 
urea reactions. Gram-positive bacteria were considered to be Staphylococcus aureus based on 118 
positive catalase and coagulase reactions (bioMérieux; Ref. 73112) and Staphylococcus spp. in the 119 
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case of positive catalase and negative coagulase results. Identification of S. uberis was based on 120 
negative response in the catalase reaction and positive response in the esculin reaction (bioMerieux; 121 
Ref 42086) (National Mastitis Council, 1999). In addition, susceptibility to penicillin was evaluated. 122 
This procedure increases specificity by excluding enterococcal isolates, which are more likely to be 123 
penicillin-resistant than streptococci (Makovec and Ruegg, 2003; Nam et al., 2010).  Susceptibility to 124 
penicillin was tested using the disc diffusion method in accordance with the recommendations of the 125 
Société Française de Microbiologie (Soussy, 2013). Using a swab, a Mueller Hinton agar plate 126 
containing 5% sheep blood (MH2, bioMérieux; Ref. 43321) was homogenously plated with a 127 
suspension of S. uberis at 0.5 McFarland (equivalent to approximately 108 colony forming units/ml). 128 
Plates were incubated at 37°C for 18 to 24 h.  Bacteria were considered sensitive to penicillin if they 129 
expressed a growth inhibition zone of more than 21 mm around an Oxacillin disc (5 µg; Soussy, 130 
2013). Bacteria that could not be classified using the criteria described here were considered “other 131 
species”. 132 
 133 
Cow and Herd Data 134 
Three data sources were used to obtain information about individual cows and their herds of origin, 135 
i.e. (i) private farm records on treatment; (ii) monthly DHI data; and (iii) questionnaires that were 136 
filled out by the farmer and the attending veterinarian. For each cow the date of mastitis diagnosis 137 
(observation of clinical mastitis or notification of SCC data via DHI) and treatment were recorded, 138 
including use of intramammary administration of antimicrobials (IMM), parenteral administration of 139 
antimicrobials (PAR), and use of non-steroidal anti-inflammatory drugs (NSAIDs). DHI data were 140 
collected from the 3 milk recordings preceding the diagnosis of mastitis, the month of diagnosis and 141 
the 3 recordings after diagnosis, if available. This included cow-level SCC data, parity (1 = first 142 
lactation, 2 = second lactation, 3 = third or higher lactation), DIM, milk yield (MY, in kg), fat content 143 
(g/kg), and protein content (g/kg). At herd level, information was collected on the use of pre-milking 144 
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teat disinfection (PreMTD) and post-milking teat disinfection (PostMTD), use of housing (yes or no) 145 
and, where applicable, on housing type (cubicles or straw yards).  146 
 147 
Classification of Cases 148 
Clinical manifestation was classified into four categories based on clinical severity of the current 149 
episode and information on previous episodes of CM in the same animal:  150 
 151 
1. Severe: CM with both local and general symptoms (T > 39°C; temperature measured on 152 
clinical suspicion of fever by the farmers and results recorded on the data form 153 
accompanying the milk sample); 154 
2. Non-severe first case (“first”): first episode of CM during the current lactation with local 155 
signs only (abnormalities of milk with or without abnormalities of the udder); 156 
3. Non-severe repeat case (“repeat”): 2nd or subsequent episode of CM during the current 157 
lactation with local signs only in the current episode (abnormalities of milk with or 158 
without abnormalities of the udder); 159 
4. Subclinical: SCC > 200,000 cells/ml at cow level based on most recent DHI data, not 160 
accompanied by any clinical signs 161 
 162 
For 212 of the 251 S. uberis positive animals SCC data were partially available (fewer than 3 records 163 
before or after diagnosis) or complete (3 records before and after diagnosis). SCC data were used to 164 
classify the duration of inflammation prior to diagnosis and the response to treatment after 165 
diagnosis. Inflammation was considered short if at least 2 monthly SCC records prior to diagnosis 166 
were below 200,000 cells/ml (SHORT) and long if at least 2 monthly SCC records exceeded 200,000 167 
cells/ml prior to diagnosis (LONG). An animal was considered cured if at least 2 monthly SCC after 168 
diagnosis were below 200,000 cells/ml (CURE) and not cured if at least 2 monthly SCC exceeded 169 
200,000 cells/ml after diagnosis (NO CURE). For other SCC combinations or missing data, duration 170 
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and cure were not determined (ND), e.g. for animals in early lactation or for cows that were dried-171 
off or culled prior to completion of follow-up.   172 
 173 
Statistical Analysis 174 
Statistical analyses were performed using Statistix, version 10 (Analytical Software, Tallahassee, FL). 175 
Data were inspected for outliers and missing values and descriptive analyses were conducted using 176 
tabular and graphical formats. For outcomes of interest with 3 or more categories, data were 177 
analysed using categorical methods (Chi-Square analyses), e.g. for cow-level factors associated with 178 
clinical severity. The association between clinical severity and milk, fat or protein yield relative to 179 
occurrence of mastitis was evaluated using a t-test at each time point. To identify cow- and herd 180 
level risk factors for apparent cure as based on SCC, logistic regression was used with backward 181 
stepwise analysis. The final logistic regression equation was: 182 
 183 
Logit (SCC cure) = intercept + Clinical manifestation + Duration + Parity + Treatment + error 184 
 185 
where Clinical manifestation is severe, first, repeat or subclinical as defined above, Duration is the 186 
inflammation history based on SCC (short, long, ND), parity is parity group (1, 2, 3+), DIM is 187 
categorized into early, mid and late lactation (<100, 100-200, 200+) and treatment is treatment for 188 
mastitis (IMM, PAR, and NSAIDs, or no treatment). Two way interactions between the main variables 189 
were also evaluated for statistical significance. No correction was made for clustering of cases within 190 
herd, because the model would not converge when herd was included due to the large number of 191 
herds and the limited number of cases per herd.  Goodness of fit of the final model was evaluated 192 
using the model deviance and the Hosmer-Lemeshow statistic. In the Hosmer-Lemeshow statistic, 193 
the data are divided into 10 approximately equal deciles of observed risk. In these deciles the 194 
observed and expected number of observation are compared using a Chi-square distribution with 195 
10-2 = 8 degrees of freedom (Hosmer and Lemeshow, 2013). A low value of the Hosmer-Lemeshow 196 
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statistic indicates a good fit to the data. In addition, a deviance value that is close to the remaining 197 
degrees of freedom implies that there is no evidence of a poor fit of the model to the data.  198 
  199 
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RESULTS 200 
 201 
Descriptive Analysis 202 
Of 624 milk samples submitted for culture 251 (40%) were positive for S. uberis in pure culture whilst 203 
42 samples (7%) were culture negative. The remaining samples tested positive for Escherichia coli (n 204 
= 108; 17%), Klebsiella (n = 12; 2 %), Staphylococcus aureus (n = 76; 12%), Staphylococcus spp. (n = 205 
103; 17%) or other species (n = 32; 5%). Samples positive for S. uberis originated from 142 farms. 206 
From 99 farms, a single S. uberis positive sample was obtained whilst 20 and 23 farms provided 2 or 207 
more S. uberis positive samples, respectively. All isolates originated from cows with clinical or 208 
subclinical mastitis in one quarter with the exception of three cows where S. uberis was isolated 209 
from two quarters on the same sampling date. The clinical manifestation of S. uberis positive 210 
mastitis cases was significantly different from the clinical manifestation of S. uberis negative cases 211 
(Chi-square = 38.0, df = 3, P < 0.005; Figure 1), with S. uberis overrepresented among non-severe 212 
first cases and underrepresented among subclinical cases. Distribution across parities was not 213 
different between S. uberis and other diagnoses (Chi-square = 1.56, df = 2, P = 0.46). During the first 214 
100 days of lactation S. uberis was less common than other diagnoses, whereas it was more common 215 
between 100 and 200 DIM (Chi-square=10.13, df = 2, P < 0.05). Milk yield, fat and protein content 216 
were not different between S. uberis and non S. uberis cases prior to infection (results not shown).  217 
Cow level data for S. uberis cases are summarized in Table 1. Severe and subclinical S. uberis 218 
cases were overrepresented in parity 1 compared to higher parities, whereas non-severe first cases 219 
were overrepresented in parity 2 and repeat cases in higher parities, respectively (Chi-square = 220 
13.67, df = 6, P < .05). Severe cases were overrepresented in early lactation, whereas repeat cases 221 
were overrepresented in mid-lactation (Chi-square = 13,02, df = 6, P < 0.05; Table 1). Treatment 222 
records were available for ca. 80% of severe, first and repeat cases and for 42% of subclinical cases 223 
(Chi-square = 22, df = 3, P = 0.0001). When no treatment was recorded, this was considered to 224 
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indicate that no treatment was administered. Intramammary antibiotics as the only treatment were 225 
more commonly used to treat non-severe first cases as compared to severe, repeated and 226 
subclinicial cases, whereas they were more commonly used in combination with parenteral 227 
treatment for repeat cases and subclinical cases (Chi-square = 31; df =6, P < 0.0001; Table 1). The 228 
combination of intramammary and parenteral antimicrobials with anti-inflammatory treatment was 229 
mostly used in severe cases and never for subclinical cases (Table 1). Milk production was 230 
numerically lower in severe cases than in non-severe cases, both before and after diagnosis of 231 
clinical or subclinical mastitis, with the exception of yield at 3 DHI recordings prior to diagnosis, but 232 
the difference was not significant. No differences were detected between severity classes with 233 
regard to fat and protein content of milk before or after diagnosis of mastitis (data not shown). 234 
 Herd-level data was collected on farms with S. uberis positive results and is presented in 235 
Table 2. Most herds were housed, either full time or part time. Straw yards were the predominant 236 
housing system, with only 22% of herds housed in cubicles. PostMTD was used in almost all herds 237 
and in more than half of all herds both PreMTD and PostMTD were used. Use of PreMTD without 238 
PostMTD was not reported.  Severe cases were overrepresented in herds without PostMTD (Chi-239 
square = 10.23, df = 3, P < .05). 240 
   241 
Factors Associated with Cure of S. uberis IMI 242 
Cure was evaluated based on post diagnosis SCC values and results from the regression model are 243 
shown in Table 3. A total of 125 cases had complete data and were included in this analysis. Model 244 
deviance was 127.4 on 115 degrees of freedom, i.e. the values were similar and there was no 245 
indication of a poor fit of the model to the data. In addition, the Hosmer-Lemeshow statistic was low 246 
(6.05), implying a good fit to the data. The probability of cure was significantly higher in animals in 247 
lactation 1 and 2 compared to older animals. The probability of cure increased numerically with 248 
increasing number of treatment types, i.e. from no treatment to intramammary antimicrobials only 249 
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to combined intramammary and parenteral antimicrobials, to both routes of antimicrobial 250 
administration combined with NSAID. However, there was no statistically significant difference in 251 
cure between treatments. Finally, the probability of cure was higher among IMI with a short history 252 
of inflammation than those with a long history of inflammation prior to treatment (Table 3). Clinical 253 
manifestation and herd level variables were not associated with cure. 254 
  255 
DAIRY INDUSTRY TODAY 
14 
 
DISCUSSION 256 
In this study we aimed to use routinely available herd and animal-level data to support control of S. 257 
uberis mastitis and the judicious use of antimicrobials. Risk factors for the incidence of S. uberis 258 
mastitis (clinical mastitis or IMI) have been described at herd-level (Barkema et al., 1999; Ericsson 259 
Unnerstad et al., 2009) and animal-level (Zadoks et al., 2001; Breen et al., 2009), and the impact of 260 
different treatment regimens on the outcome of treatment of S. uberis mastitis has been described 261 
for experimentally induced (Hillerton and Kliem, 2002; Oliver et al., 2003) and naturally occurring 262 
infections (reviewed in Zadoks, 2007). To our knowledge, animal-level risk factors for severity of 263 
disease or treatment outcome of S. uberis IMI have not been described. Here, we show for the first 264 
time that animal-level data can be used to predict the outcome of antimicrobial treatment of S. 265 
uberis mastitis and to guide treatment decisions. Specifically, the probability of cure was higher 266 
among 1st and 2nd parity animals compared to older cows, and in animals with at most a single 267 
elevated cow-level SCC before diagnosis compared to those with multiple high SCC records. Those 268 
findings are strikingly similar to results obtained for Staphylococcus aureus IMI across a range of 269 
studies covering both clinical and subclinical mastitis (reviewed in Barkema et al., 2006) and can be 270 
used to inform decisions about treatment duration or the choice between treatment and culling. The 271 
individual making treatment decisions will be able to weigh these factors in the decision making and 272 
to use this information to provide a realistic prognosis. Pathogen-specific predictors for cure, as 273 
described here for S. uberis, are particularly useful when information on the causative agent is 274 
available.  Several studies have demonstrated the feasibility of using on-farm diagnostics to inform 275 
case management (Lago et al., 2011; Cameron et al., 2014) and additional tests for rapid or on-farm 276 
screening of milk samples are under development, including culture and DNA-based tests (Viora et 277 
al., 2014; Bosward et al., 2016). Considering the similarities between results obtained for S. uberis 278 
and S. aureus, some of this information may also be of value in the absence of an etiological 279 
diagnosis, although further field evaluation will be needed to validate such a generic approach.  280 
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Increased parity was associated with a reduced likelihood of cure. This is not merely a 281 
reflection of the chronicity of infection, because parity was significant after correction for SCC, which 282 
is a proxy for duration (Barkema et al., 2006). The mechanism behind reduced probability of cure in 283 
older animals is unknown. Possible explanations were discussed by Barkema and co-workers (2006) 284 
for the response to treatment of Staph. aureus IMI. One potential explanation is the change in ratio 285 
between udder volume, which increases with age, and the administered dose of antimicrobials, 286 
which is independent of age, resulting in a lower dose per unit udder volume in older animals 287 
(Barkema et al., 2006). This reasoning would also apply to S. uberis treatment. Immunosenescence, 288 
the waning of the immune response with age, could be postulated to play a role in deterioration of 289 
treatment outcome with age, but there is no specific evidence for this in the context of bovine 290 
mastitis. Regardless of the underlying mechanism, the comparatively poor treatment response of 291 
older cows can be interpreted as an imperative to help our cows to age healthily, e.g. by selecting 292 
for cows with high genetic merit for udder health or immune responsiveness (Thompson-Crispi et al., 293 
2014). In addition, animal-level risk factors should be minimized where possible.  For example, 294 
severe teat end hyperkeratosis is an animal-level risk factor for S. uberis CM, and the risk of 295 
hyperkeratosis can be reduced by avoiding overmilking (Breen et al., 2009; Edwards et al., 2013).  296 
 The observation that duration of IMI, as measured by number of elevated monthly SCC prior 297 
to treatment, is predictive of cure is compatible with previous data on both S. uberis and Staph. 298 
aureus. A detailed longitudinal study of S. uberis IMI in 2 herds showed that some episodes of CM 299 
are due to recent IMI, whereas other CM episodes are preceded by periods of elevated (Zadoks et 300 
al., 2003). CM episodes without preceding SCC elevation were more likely to be followed by cure 301 
than CM episodes with preceding SCC elevation. Similarly, in several treatment trials of Staph. 302 
aureus IMI, higher or longer SCC elevation prior to treatment was associated with a decreased 303 
probability of cure (reviewed in Barkema et al., 2006). A poor response of chronic Staph. aureus IMI 304 
to treatment may be explained in part by micro-abscess formation and fibrosis (Erskine et al., 2003). 305 
Fibrosis also occurs during S. uberis mastitis, starting as early as 6 days after infection in 306 
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experimental challenge studies. It is accompanied by presence of the pathogen in subepithelial and 307 
septal tissue and lymphatic vessels and lymph nodes (Thomas et al., 1994). This may explain why the 308 
response of S. uberis mastitis to treatment can be poor, even after extended therapy (Milne et al., 309 
2005). Both in experimentally induced and in persistent S. uberis IMI, extended therapy increases 310 
the probability of cure (Oliver et al., 2003; Swinkels et al., 2014). The benefits of extended therapy 311 
must be weighed against its disadvantages, including increased costs of antibiotics and milk discard, 312 
and increased risk of residue in milk and selection for antimicrobial resistance (Hillerton and Kliem, 313 
2002; Barkema et al., 2006). As in any risk factor study, the risk factors identified in the current 314 
study, including treatment modality, and their coefficients allow us to quantify the increase or 315 
decrease in the likelihood of a particular treatment outcome, but the specific outcome in any 316 
individual animal cannot be predicted. 317 
 In the current study a numerical but non-significant increase in cure was observed with an 318 
increase in treatment modalities (intramammary and parenteral antimicrobials and NSAIDs). This 319 
study was not, however, a randomized controlled clinical trial, nor was it meant to be. Farmers 320 
tended to treat severe cases of mastitis with a combination of intramammary, parenteral and anti-321 
inflammatory products, first clinical cases with intra-mammary treatment only and repeated- and 322 
subclinical cases with antimicrobial treatment by both the intra-mammary and parenteral route.  323 
This implies farmers’ awareness of the usefulness of cow-specific treatment, with consideration of 324 
both animal welfare and economic aspects of treatment. This information provides evidence that 325 
farmers are willing to make cow-specific decisions and bodes well for the feasibility of including cow-326 
specific risk factors in future protocols. In our practice, farm specific treatment protocols are already 327 
discussed with each farmer on an annual basis and the treatment choices reported by the farmers 328 
are in line with those protocols. As a next step towards judicious use of antimicrobials, we envisage 329 
implementation of cow-specific protocols. 330 
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Animals with short duration mastitis (no or single SCC elevation prior to diagnosis) were 331 
likely to cure (no or single SCC elevation after diagnosis), whereas animals with long duration 332 
mastitis (multiple SCC elevation prior to diagnosis) were likely not to cure (multiple SCC elevations 333 
after diagnosis). Similarly, data availability post-diagnosis mirrored data availability pre-diagnosis, i.e. 334 
animals with incomplete SCC data prior to diagnosis often had incomplete SCC data after diagnosis 335 
too (data not shown). This would mostly apply to animals in early lactation that were lost to follow-336 
up due to culling. Thus, although our analysis shows no significant difference in cure between 337 
different severity classes, this result is affected by “healthy worker bias”, whereby only surviving 338 
cows are included in the analysis. Indeed, loss to follow-up as indicate by absence of data on cure 339 
was proportionally higher for severe cases than for non-severe cases (Table 1). 340 
Of the herd-level factors considered in this study, use of PostMTD was associated with a 341 
reduced risk of severe, repeat and subclinical S. uberis mastitis compared to first cases of mastitis. 342 
The value of PostMTD in reducing the risk of S. uberis IMI has been documented repeatedly (Zadoks 343 
et al., 2003; Galton, 2004; Williamson and Lacy-Hulbert, 2013) but it has not been linked to clinical 344 
manifestation. Strain-specific transmission and virulence patterns have previously been suggested or 345 
documented (Zadoks et al., 2003; Tassi et al., 2013) and could theoretically contribute to an 346 
association between PostMTD and clinical manifestation. It has also been hypothesized that host 347 
immune status may contribute to clinical manifestation of S. uberis IMI (Tassi et al., 2013). Indeed, in 348 
the current study, severe cases of CM were overrepresented among heifers and animals in early 349 
lactation. This emphasizes the importance of another herd-level management factor, i.e. adequate 350 
care for non-lactating animals. Considering that S. uberis is common in the faeces and environment 351 
of cattle (Zadoks et al., 2005), environmental hygiene is of particular importance. The risk of 352 
infection in heifers and dry cows can also be reduced through use of teat spray and internal teat 353 
sealants, respectively (Lopez-Benavides et al., 2009; Compton et al., 2014). With increasing pressure 354 
to reduce antimicrobial use, implementation of non-antimicrobial mastitis prevention measures 355 
becomes increasingly important. 356 
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In this field study, definitions of transient and persistent IMI and cure were based on SCC 357 
data. Although repeated post-treatment culture has been considered the “gold standard” for cure in 358 
clinical trials, additional or alternative metrics for cure are increasingly reported in field studies. SCC 359 
has been used as a primary criterion for cure in studies of clinical mastitis, subclinical mastitis, and 360 
dry cow treatment (St. Rose et al., 2003; Lago et al., 2011; Persson et al., 2015). SCC is routinely used 361 
as an indicator of infection status (Schukken et al., 2003), although the probability of bacteriological 362 
cure is higher than the probability of SCC-based cure in studies of chronic streptococcal mastitis (St. 363 
Rose et al., 2003). SCC is of immediate interest to farmers, unlike bacteriological cure which is 364 
primarily of academic interest. Moreover, SCC is routinely available at very low cost, which makes its 365 
large-scale use feasible in field studies, veterinary practice and farm management. Finally, SCC 366 
captures long-term outcomes of mastitis treatment, whereas culture results generally only reflect 367 
the first few weeks post-treatment. Thus, SCC is a convenient, affordable and meaningful indicator 368 
of treatment outcome.  369 
In conclusion, we show that treatment recommendations can be informed by animal-level 370 
data that is routinely available to farmers and veterinarians, such as parity and SCC. To some extent, 371 
treatment recommendations can be animal-specific rather than pathogen-specific, as both S. uberis 372 
IMI and Staph. aureus IMI show a better response to treatment in animals in first or second lactation 373 
and in animals with a single high SCC than in older animals or animals with multiple high SCC values 374 
prior to treatment. In older animals or animals with multiple high SCC values the simultaneous use of 375 
multiple treatment modalities may enhance the probability of cure but this would result in increased 376 
use of antimicrobials. To limit the need for such treatment, continued or renewed emphasis on herd 377 
management and infection prevention is needed. Formal validation of the observations described 378 
here through a randomized controlled clinical trial may strengthen the evidence base underpinning 379 
the suggested treatment decisions. In the absence of such validation, the evidence presented here is 380 
the best available evidence to inform decisions on treatment of S. uberis mastitis, the most common 381 
type of mastitis observed in this and many other studies.   382 
DAIRY INDUSTRY TODAY 
19 
 
Bibliography 383 
1. Barkema, H. W., Y. H. Schukken, T. J. Lam, M. L. Beiboer, G. Benedictus, and A. 1999. 384 
Management practices associated with the incidence rate of clinical mastitis. J Dairy Sci. 385 
82:1643-54. 386 
2. Barkema, H. W., Y. H. Schukken, and R. N. Zadoks. 2006. Invited Review: The role of cow, 387 
pathogen, and treatment regimen in the therapeutic success of bovine Staphylococcus aureus 388 
mastitis. J Dairy Sci. 89:1877-95. 389 
3. Bosward K.L., J. K. House, A. Deveridge, K. Mathews, and P. A. Sheehy. 2016. Development of a 390 
loop-mediated isothermal amplification assay for the detection of Streptococcus agalactiae in 391 
bovine milk. J Dairy Sci. 99:2142-50. 392 
4. Bradley, A. J., K. A. Leach, J. E. Breen, L. E. Green, and M. J. Green MJ. 2007. Survey of the 393 
incidence and aetiology of mastitis on dairy farms in England and Wales. Vet Rec. 160:253-7. 394 
5. Breen, J. E., M. J. Green, and A. J. Bradley AJ. 2009. Quarter and cow risk factors associated with 395 
the occurrence of clinical mastitis in dairy cows in the United Kingdom. J Dairy Sci. 92:2551-61. 396 
6. Cameron, M., S. L. McKenna, K. A. MacDonald, I. R. Dohoo, J. P. Roy, and G. P. Keefe. 2014. 397 
Evaluation of selective dry cow treatment following on-farm culture: risk of postcalving 398 
intramammary infection and clinical mastitis in the subsequent lactation. J Dairy Sci. 97:270-84. 399 
7. Compton, C. W., F. R. Emslie, and S. McDougall. 2014. Randomised controlled trials 400 
demonstrate efficacy of a novel internal teat sealant to prevent new intramammary infections 401 
in dairy cows and heifers. N Z Vet J. 62:258-66. 402 
8. Edwards, J.P., B. O'Brien, N. Lopez-Villalobos, and J. G. Jago JG. 2013. Overmilking causes 403 
deterioration in teat-end condition of dairy cows in late lactation. J Dairy Res. 80:344-8. 404 
9. Ericsson Unnerstad, H., A. Lindberg, K. Persson Waller, T. Ekman, K. Artursson, M. Nilsson-Ost, 405 
and B. Bengtsson. 2009. Microbial aetiology of acute clinical mastitis and agent-specific risk 406 
factors. Vet Microbiol. 137:90-7. 407 
DAIRY INDUSTRY TODAY 
20 
 
10. Erskine, R. J., S. Wagner, and F. J. DeGraves. 2003. Mastitis therapy and pharmacology. Vet Clin 408 
North Am Food Anim Pract. 19:109-38. 409 
11. Galton, D. M. 2004. Effects of an automatic postmilking teat dipping system on new 410 
intramammary infections and iodine in milk. J Dairy Sci. 87:225-31. 411 
12. Hillerton, J. E., and K. E. Kliem. 2002. Effective treatment of Streptococcus uberis clinical mastitis 412 
to minimize the use of antibiotics. J Dairy Sci. 85:1009-14. 413 
13. Hosmer, D. W., and S. Lemeshow. 2013. Applied Logistic Regression. New York, Wiley. 414 
14. Jones, P. J., E. A. Marier, R. B. Tranter, G. Wu, E. Watson, and C. J. Teale CJ. 2015. Factors 415 
affecting dairy farmers' attitudes towards antimicrobial medicine usage in cattle in England and 416 
Wales. Prev Vet Med. 121:30-40. 417 
15. Lago, A., S. M. Godden, R. Bey, P. L. Ruegg, and K. Leslie. 2011. The selective treatment of 418 
clinical mastitis based on on-farm culture results: II. Effects on lactation performance, including 419 
clinical mastitis recurrence, somatic cell count, milk production, and cow survival. J Dairy Sci. 420 
94:4457-67. 421 
16. Lopez-Benavides, M. G., J. H. Williamson, S. J. Lacy-Hulbert, and R. T. Cursons RT. 2009. Heifer 422 
teats sprayed in the dry period with an iodine teat sanitizer have reduced Streptococcus uberis 423 
teat-end contamination and less Streptococcus uberis intra-mammary infections at calving. Vet 424 
Microbiol. 134:186-91. 425 
17. Makovec, J. A., and P. L. Ruegg. 2003. Antimicrobial resistance of bacteria isolated from dairy 426 
cow milk samples submitted for bacterial culture: 8,905 samples (1994-2001). J Am Vet Med 427 
Assoc. 222:1582-9. 428 
18. Milne, M. H., A. M. Biggs, D. C. Barrett, F. J. Young, S. Doherty, G. T. Innocent, and J. L. 429 
Fitzpatrick. 2005. Treatment of persistent intramammary infections with Streptococcus uberis in 430 
dairy cows. Vet Rec. 157:245-50. 431 
DAIRY INDUSTRY TODAY 
21 
 
19. Nam, H. M., S. K. Lim, J. S. Moon, H. M. Kang, J. M. Kim, K. C. Jang, J. M. Kim, M. I. Kang, Y. S. 432 
Joo, and S. C. Jung. 2010 Antimicrobial resistance of enterococci isolated from mastitic bovine 433 
milk samples in Korea. Zoonoses Public Health.;57:e59-64. 434 
20. National Mastitis Council. 1999. Laboratory handbook on bovine mastitis, National Mastitis 435 
Council, Madison, WI.  436 
21. Olde Riekerink, R. G., H. W. Barkema, D. F. Kelton, and D. T. Scholl DT. 2008. Incidence rate of 437 
clinical mastitis on Canadian dairy farms. J Dairy Sci. 91:1366-77. 438 
22. Oliver, S. P., R. A. Almeida, B. E. Gillespie, S. J. Ivey, H. Moorehead, P. Lunn, H. H. Dowlen, D. L. 439 
Johnson, and K. C. Lamar KC. 2003. Efficacy of extended pirlimycin therapy for treatment of 440 
experimentally induced Streptococcus uberis intramammary infections in lactating dairy cattle. 441 
Vet Ther. 4:299-308. 442 
23. Pol, M., and P. Ruegg. 2007. Treatment practices and quantification of antimicrobial drug usage 443 
in conventional and organic dairy farms in Wisconsin.  J Dairy Sci. 90:249-61.  444 
24. Persson, Y., J. Katholm, H. Landin, and M. J. Mörk. 2015. Efficacy of enrofloxacin for the 445 
treatment of acute clinical mastitis caused by Escherichia coli in dairy cows. Vet Rec. 176:673. 446 
25. Petrovski, K. R., N. B. Williamson, N. Lopez-Villalobos, T. J. Parkinson, and I. G. Tucker. 2011. 447 
Culture results from milk samples submitted to veterinary diagnostic laboratories from August 448 
2003 to December 2006 in New Zealand. N Z Vet J.59:317-22. 449 
26. Raymond, M. J., R. D. Wohrle, and D. R. Call DR. 2006. Assessment and promotion of judicious 450 
antibiotic use on dairy farms in Washington State. J Dairy Sci. 89:3228-40. 451 
27. Sampimon, O., H. W. Barkema, I. Berends, J. Sol, and T. Lam. 2009. Prevalence of intramammary 452 
infection in Dutch dairy herds. J Dairy Res. 76:129-36. 453 
28. Scherpenzeel, C. G., I. E. den Uijl, G. van Schaik, R. G. Olde Riekerink, J. M. Keurentjes, and T. J. 454 
Lam. 2014. Evaluation of the use of dry cow antibiotics in low somatic cell count cows. J Dairy 455 
Sci. 97:3606-14. 456 
DAIRY INDUSTRY TODAY 
22 
 
29. Schukken, Y. H., D. J. Wilson, F. Welcome, L. Garrison-Tikofsky, and R. N. González. 2003. 457 
Monitoring udder health and milk quality using somatic cell counts. Vet Res. 34:579-96. 458 
30. Soussy, C. J. 2013. Recommendations 2013: Communique du Comité de l'antibiogramme de la 459 
Société Française de Microbiologie, Institut Pasteur, Paris. 460 
31. St Rose, S. G., J. M. Swinkels, W. D. Kremer, C. L. Kruitwagen, and R. N. Zadoks. 2003. Effect of 461 
penethamate hydriodide treatment on bacteriological cure, somatic cell count and  milk 462 
production of cows and quarters with chronic subclinical Streptococcus uberis or Streptococcus 463 
dysgalactiae infection. J Dairy Res. 2003 Nov;70(4):387-94. 464 
32. Swinkels, J. M., V. Krömker, and T. J. Lam. 2014. Efficacy of standard vs. extended 465 
intramammary cefquinome treatment of clinical mastitis in cows with persistent high somatic 466 
cell counts. J Dairy Res. 81:424-33. 467 
33. Tassi, RT. N. McNeilly, J. L. Fitzpatrick, M. C. Fontaine, D. Reddick, C. Ramage, M. Lutton, Y. H. 468 
Schukken, and R. N. Zadoks. 2013. Strain-specific pathogenicity of putative host-adapted and 469 
nonadapted strains of Streptococcus uberis in dairy cattle. J Dairy Sci. 96:5129-5145. 470 
34. Thomas, L. H., W. Haider, A. W. Hill, and R. S. Cook RS. 1994. Pathologic findings of 471 
experimentally induced Streptococcus uberis infection in the mammary gland of cows. Am J Vet 472 
Res. 55:1723-8. 473 
35. Thompson-Crispi, K., H. Atalla, F. Miglior, and B. A. Mallard. 2014. Bovine mastitis: frontiers in 474 
immunogenetics. Front Immunol. 5:493.  475 
36. UK Department of Health. 2013. UK Five Year Antimicrobial Resistance Strategy 2013 to 2018. 476 
www.gov.uk/dh (last accessed 18 October 2015). 477 
37. Viora, L., E. M. Graham, D. J. Mellor, K. Reynolds, P. B. Simoes, and T. E. Geraghty. 2014. 478 
Evaluation of a culture-based pathogen identification kit for bacterial causes of bovine mastitis. 479 
Vet Rec. 175:89. 480 
38. Williamson, J. H., and S. J. Lacy-Hulbert. 2013. Effect of disinfecting teats post-milking or pre- 481 
and post-milking on intramammary infection and somatic cell count. N Z Vet J. 61:262-8. 482 
DAIRY INDUSTRY TODAY 
23 
 
39. World Health Organisation. 2015. http://www.who.int/mediacentre/news/releases/2015/wha-483 
25-may-2015/en/ (last accessed 18 October 2015). 484 
40. Zadoks, R. N. 2007. Sources and epidemiology of Streptococcus uberis, with special emphasis on 485 
mastitis in dairy cattle. CAB Reviews: Perspectives in Agriculture, Veterinary Science, Nutrition 486 
and Natural Resources, 2, 030, 15 pp. 487 
41. Zadoks, R. N., H. G. Allore, H. W. Barkema, O. C. Sampimon, G. J. Wellenberg, Y. T. Gröhn, Y. H. 488 
Schukken. 2001. Cow- and quarter-level risk factors for Streptococcus uberis and Staphylococcus 489 
aureus mastitis. J Dairy Sci. 84:2649-63. 490 
42. Zadoks, R. N., B. E. Gillespie, H. W. Barkema, O. C. Sampimon, S. P. Oliver, Y. H. Schukken. 2003. 491 
Clinical, epidemiological and molecular characteristics of Streptococcus uberis infections in dairy 492 
herds. Epidemiol Infect. 130:335-49.  493 
43. Zadoks, R. N., L. L. Tikofsky, and K. J. Boor KJ. 2005. Ribotyping of Streptococcus uberis from a 494 
dairy's environment, bovine feces and milk. Vet Microbiol. 109:257-65. 495 
  496 
DAIRY INDUSTRY TODAY 
24 
 
Figure legend 497 
Figure 1. Clinical manifestation of mastitis for quarters with S. uberis negative (n = 373, white) and S. 498 
uberis positive (n =251, black) milk samples (Chi-square = 38.0, df = 3, P < 0.005). Severe: clinical 499 
mastitis (CM) with local and general symptoms (T > 39°C; checked upon clinical suspicion of fever); 500 
Non-severe first case: first occurrence of CM during the current lactation with local signs only 501 
(abnormalities of milk with or without abnormalities of the udder). Non-severe repeat case: repeat 502 
occurrence of CM during the current lactation with local signs only during the current episode; 503 
Subclinical mastitis: elevated cow-level SCC (> 200.000 cells/ml based on DHI data) not accompanied 504 
by any visible abnormalities.  505 
  506 
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Table 1. Cow- level data for S. uberis positive mastitis cases (number and (%)) with break-down by 523 
manifestation. Severe: clinical mastitis (CM) with local and general symptoms (T > 39°C; checked 524 
upon clinical suspicion of fever); First: first occurrence of CM during the current lactation with local 525 
signs only (abnormalities of milk with or without abnormalities of the udder). Repeat: repeat 526 
occurrence of CM during the current lactation with local signs only during current episode; 527 
Subclinical: cow-level SCC (> 200,000 cells/ml based on DHI data) not accompanied by any signs.  528 
 529 
Cow factor  All S. uberis cases, 
n (%) 
S. uberis cases by clinical manifestation, n (%) 
Severe First Repeat Subclinical 
DIM 
   <100 
   100 to 200 
   > 200 
   subtotal 
 
123 (100) 
63 (100) 
50 (100) 
236 (100) 
 
26 (21) 
7 (11) 
4 (8) 
37 (16) 
 
56 (46) 
25 (40) 
24 (48) 
105 (44) 
 
27 (22) 
27 (43) 
17 (34) 
71 (30) 
 
14 (11) 
4 (6) 
5 (10) 
23 (10) 
Parity 
   First 
   Second 
   Higher 
   subtotal 
 
61 (100) 
55 (100) 
122 (100) 
238 (100) 
 
12 (20) 
7 (13) 
17 (14) 
36 (15) 
 
23 (38) 
34 (62) 
49 (40) 
106 (45) 
 
16 (26) 
12 (22) 
44 (36) 
72 (30) 
 
10 (16) 
2 (4) 
12 (10) 
24 (10) 
Treatment1 
   none 
   IMM 
   IMM + PAR 
   IMM + PAR + NSAID 
   subtotal 
 
49 (100) 
67 (100) 
103 (100) 
19 (100) 
238 (100) 
 
7 (14) 
6 (9) 
14 (14) 
10 (53) 
37 (16) 
 
17 (35) 
42 (63) 
41 (40) 
6 (32) 
106 (45) 
 
12 (24) 
17 (25) 
40 (39) 
3 (16) 
 72 (30) 
 
13 (27) 
2 (3) 
8 (12) 
0 (0) 
23 (10) 
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Duration2 
   Short 
   Long 
   ND 
   subtotal 
 
78 (100) 
66 (100) 
96 (100) 
240 (100) 
 
8 (10) 
8 (12) 
22 (23) 
38 (16) 
 
35 (45) 
25 (38) 
46 (48) 
106 (44) 
 
30 (38) 
23 (35) 
19 (20) 
72 (30) 
 
5 (6) 
10 (15) 
9 (9) 
24 (10) 
Cure 
   Yes 
   No 
   ND 
   subtotal 
 
79 (100) 
97 (100) 
64 (100) 
240 (100) 
 
10 (13) 
12 (12) 
16 (25) 
38 (16) 
 
39 (49) 
38 (39) 
29 (45)  
106 (44) 
 
23 (29) 
33 (34) 
16 (25) 
72 (30) 
 
7 (9) 
14 (14) 
3 (5) 
24 (10) 
 530 
1. Treatment: IMM = intra-mammary antibiotic treatment, PAR= parenteral antibiotic treatment, 531 
NSAID = non-steroidal anti-inflammatory drugs. 532 
2. Duration: Short = at least 2 monthly cow-level SCC < 200,000 cells/ml before diagnosis; Long = 533 
at least 2 monthly cow-level SCC > 200,000 cells/ml before diagnosis; ND = not determined due 534 
to insufficient SCC data before diagnosis. 535 
3. Cure: Yes = at least 2 monthly cow-level SCC < 200,000 cells/ml after diagnosis; Long = at least 2 536 
monthly cow-level SCC > 200,000 cells/ml after diagnosis; ND = not determined due to 537 
insufficient SCC data after diagnosis.  538 
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Table 2. Herd-level data for S. uberis positive mastitis cases (number and (%)) with breakdown by 539 
manifestation. Severe: clinical mastitis (CM) with local and general symptoms (T > 39°C; checked 540 
upon clinical suspicion of fever); First: first occurrence of CM during the current lactation with local 541 
signs only (abnormalities of milk with or without abnormalities of the udder). Repeat: repeat 542 
occurrence of CM during the current lactation with local signs only during current episode; 543 
Subclinical: cow-level SCC (> 200.000 cells/ml based on DHI data) not accompanied by any signs. 544 
 545 
Herd factor  All S. uberis cases, 
n (%) 
S. uberis cases by clinical manifestation, n (%) 
Severe First Repeat Subclinical 
Housing 
   Permanent 
   Partial 
   None 
   subtotal 
 
120 (100) 
92 (100) 
28 (100) 
240 (100) 
 
15 (13) 
20 (22) 
3 (29) 
38 (16) 
 
57 (48) 
32 (35) 
17 (61) 
106 (44) 
 
39 (33) 
28 (30) 
5 (18) 
72 (30) 
 
9 (8) 
12 (13) 
3 (11) 
24 (10) 
Bedding 
   Straw yard 
   Cubicles 
   Subtotal 
 
187 (100) 
53 (100) 
240 (100) 
 
27 (11) 
11 (21) 
38 (16) 
 
84 (45) 
22 (42) 
106 (44) 
 
58 (31) 
14 (26) 
72 (30) 
 
18 (75) 
6 (25) 
24 (100) 
Pre-dipping 
   Yes 
   No 
   Subtotal 
 
130 (100) 
106 (100) 
236 (100) 
 
19 (15) 
18 (17) 
37 (16) 
 
56 (43) 
48 (45 
104 (44) 
 
44 (34) 
27 (25) 
71 (30) 
 
11 (8 
13 (12) 
24 (10) 
Post-dipping 
   Yes 
   No 
   Subtotal 
 
214 (100) 
22 (100) 
236 (100) 
 
29 (14) 
8 (36) 
37 (16) 
 
94 (44) 
10 (45) 
104 (44) 
 
67 (31)  
4 (18) 
71 (30) 
 
24 (11) 
0 (0) 
24 (10) 
  546 
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Table 3. Logistic regression of cow-factors versus cure for 125 cases of S. uberis mastitis.  547 
 548 
Variable Coefficient (SE) Odds Ratio 
95% C.I. for 
Odds Ratio Z-value P-value 
Constant -4.8 (1.3) 
  
-3.68 0.0002 
Parity     
     First 1.7 (0.6) 5.5 1.8 to 5.5 3.1 0.0023 
     Second 1.3 (0.6) 3.8 1.3 to 11.1 2.42 0.016 
     Third or higher Base 
    Clinical manifestation1  
     Severe 1.6 (1.3) 4.8 0.3 to 68.7 1.16 0.24 
     First 2.0 (1.2) 7.1 0.7 to 77.0 1.65 0.10 
     Repeat 1.9 (1.2) 6.4 0.6 to  70.9 1.54 0.13 
     Subclinical Base 
    Duration 2  
     Short 1.7 (0.5) 3.1 2.2 to 14.2 3.74 0.0002 
     Long Base 
    Treatment3  
     IMM + PAR + NSAID 2.2 (1.3) 9.4 0.7 to 9.4 1.68 0.09 
     IMM + PAR 1.1 (0.6) 3.1 0.9 to 3.1 1.79 0.074 
     IMM 0.7(0.7) 2.1 0.6 to 8.2 1.09 .28 
     None Base 
     549 
1. Severe: clinical mastitis (CM) with local and general symptoms (T > 39°C; checked upon clinical 550 
suspicion of fever); First: first occurrence of CM during the current lactation with local signs only 551 
(abnormalities of milk with or without abnormalities of the udder). Repeat: repeat occurrence 552 
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of CM during the current lactation with local signs only during current episode; Subclinical: cow-553 
level SCC (> 200.000 cells/ml based on DHI data) not accompanied by any signs. 554 
2. Duration: Short = at least 2 monthly cow-level SCC < 200,000 cells/ml before diagnosis; Long = 555 
at least 2 monthly cow-level SCC > 200,000 cells/ml before diagnosis; ND = not determined due 556 
to insufficient SCC data before diagnosis. 557 
3. Treatment: IMM = intra-mammary antibiotic treatment, PAR= parenteral antibiotic treatment, 558 
NSAID = non-steroidal anti-inflammatory drugs. 559 
